[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-total-occlusion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-total-occlusion":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100526651","risk-factors-and-outcomes-in-coronary-chronic-total-occlusion-100526651",false,"NCT06137521","Risk Factors and Outcomes in Coronary Chronic Total Occlusion","Risk Factors and Outcomes in Patients With Stable Coronary Artery Disease and Coronary Chronic Total Occlusion","Inclusion Criteria:\n\n* Age ≥18 years; Patients with angina or silent ischemia and documented ischemia; Patients with CTO ≥ 3months\n\nExclusion Criteria:\n\n* eGFR\\\u003C15mL\u002F(min·1.73m2); Chronic heart failure with NYHA grade ≥3; Had a history of coronary artery bypass grafting; Had received a percutaneous coronary intervention within the prior 3 months; Malignant tumor or immune system disorders; Pulmonary heart disease","ALL","18 Years",{"count":19,"type":20},3000,"ESTIMATED","OBSERVATIONAL","This study aims to assess the risk factors and evaluate the long-term outcomes of patients with coronary chronic total occlusion (CTO) treated with percutaneous coronary intervention or medical treatment.",[24,25],"Chronic Total Occlusion","Coronary Artery Disease","RECRUITING","2026-08-17",{"date":29,"type":30},"2026-08-18","ACTUAL",{"date":32,"type":30},"2010-01-01",{"date":34,"type":20},"2027-03-01",{"name":36,"class":37},"Ruijin Hospital","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100487865","cto-pci-in-heart-failure-patients-100487865","NCT05632653","CTO-PCI in Heart Failure Patients","Percutaneous Coronary Intervention in Patients with Chronic Total Occlusion of Coronary Arteries and Heart Failure.","CTO-HF","Inclusion Criteria:\n\n* Written informed consent.\n* Presence of at least one CTO located at the proximal to midpart of left artery descending (LAD), or at proximal left circumflex (LCX), or at proximal to midpart LCX in left dominant system, or at proximal to distal right coronary artery (RCA).\n* LVEF \\\u003C50% (assessed within 6 weeks prior to enrolment by transthoracic echocardiography (TTE) (Simpson biplane method) or cardiac magnetic resonance imaging (cMRI).\n* In patients with multivessel disease (MVD) and Syntax I score ≥ 22, and all patients with type 2 diabetes and coronary 3 vessel disease, a heart team decision favouring CTO-PCI is needed.\n* Mandatory baseline imaging assessment (assessed within 6 weeks prior to enrolment):\n* TTE: Normal wall motion or hypokinesia in the CTO-territory.\n* In case of severe hypokinesia, akinesia or dyskinesia a viability testing with cMRI or myocardial scintigraphy (MS) indicating at least 50% of viability in the CTO territory (mandatory only in the presence of akinesia in the CTO-territory assessed by prior TTE) prior to PCI is mandatory.\n* Symptoms including dyspnea (according to the New York Heart Association (NYHA), classes II-III) or angina pectoris (according to Canadian Cardiovascular Society (CCS), classes II-IV).\n* In the absence of symptoms evidence of myocardial ischemia of at least 10% is needed being assessed by invasive or non-invasive imaging, such as stress-MRI, PET-CT-scan, myocardial scintigraphy, stress-echocardiography\n\nExclusion Criteria:\n\n* Age \\\u003C18 and \\>90 years.\n* Akinesia or dyskinesia assessed by TTE plus subendocardial late gadolinium enhancement of \\>50% assessed by cMRI or MS in the CTO-territory or any evidence of transmural scarring of the CTO-territory (i.e. 100%).\n* Presence of terminal kidney disease with need for renal replacement therapy.\n* Severe chronic kidney disease (defined as GFR \\\u003C 25 ml\u002Fmin).\n* Type I myocardial infarction (ST segment elevation or non-ST segment elevation myocardial infarction (STEMI or NSTEMI)) related to critical arteriosclerosis \\\u003C 30 days.\n* End-stage heart failure (defined by constant administration of intravenous inotropes, use of prolonged assist devices (more than 5 days), listing for high urgent cardiac transplantation).\n* Cardiogenic shock (\\\u003C 30 days).\n* Heart team decision favoring CABG surgery (in the presence of coronary multivessel disease with intermediate to high SYNTAX I score).\n* Grade II-III heart valve disorders requiring interventional or surgical treatment within 3 months.\n* Right-sided heart failure with echocardiographic evidence of severe right ventricular dysfunction.\n* COPD requiring long-term oxygen therapy.\n* Non-cardiac comorbidity with life expectancy \\\u003C 12 months.","90 Years",{"count":49,"type":20},783,"INTERVENTIONAL",[52],"NA","The study investigates wheather CTO-PCI improves survival and heart failure related rehospitalization compared to optimal medical therapy (OMT). This hypothesis will be investigated within a large-scaled international, representative, prospective, randomized, controlled, open-label, event-driven, multicentre trial (trial acronym: CTO - Heart Failure) recruiting patients with planned CTO-PCI.",[25,24,55],"Heart Failure","NOT_YET_RECRUITING","2024-09-15",{"date":59,"type":30},"2024-09-19",{"date":61,"type":20},"2025-09",{"date":63,"type":20},"2030-12",{"name":65,"class":37},"Universitätsmedizin Mannheim",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":50,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":4},"100529561","antiplatelet-therapy-after-successful-percutaneous-coronary-intervention-for-chronically-occluded-coronary-artery-100529561","NCT06175377","Antiplatelet Therapy After Successful Percutaneous Coronary Intervention for Chronically Occluded Coronary Artery","Antiplatelet Therapy After Successful Percutaneous Coronary Intervention for Chronically Occluded Coronary Artery: A Prospective, Multicenter, Randomized Study Comparing Two Durations of Dual Antiplatelet Therapy","DAPT-CTO","Inclusion Criteria:\n\n* Patients who underwent a successful coronary stent implantation for chronic coronary occlusion, eligible for long-term aspirin therapy and requiring a dual antiplatelet therapy\n* Affiliated to Social Security system.\n* Signature of informed consent.\n* Age \\> 18 years old.\n\nExclusion Criteria:\n\n* Dual antiplatelet therapy contra-indication\n* Patient with hypersensitivity to aspirin (or any of its excipients) and\u002For to any of the active substance or to any of the excipients of the investigational medical product used in this study (clopidogrel);\n* Patient with contraindication to aspirin and\u002For clopidogrel.\n* No coronary stent implanted\n* Age \\\u003C 18years\n* Patient under guardianship\n* Pregnancy or breast feeding\n* Prasugrel or ticagrelor use",{"count":75,"type":20},660,[52],"Coronary arteries are in charge of oxygen supply for the myocardium. When coronary arteries develop stenosis the coronary blood flow (i.e. oxygen flow) is reduced. Chronic total occlusion (CTO) is the extreme evolution of a coronary stenosis, which ends up to a total vessel closure.\n\nPercutaneous coronary intervention (PCI) is the main treatment for chronic occlusions. The principle of this treatment is to implant a stent covering the whole segment of occlusion and allowing the blood to perfuse the myocardium antegradely and not retrogradely via the collateral(s). This angioplasty and stent implantation requires a dual antiplatelet therapy (aspirin associated with clopidogrel) to prevent a new thrombosis within the newly placed coronary stent.\n\nFollowing the development of coronary stent (and particularly drug eluting coronary stent) new thrombosis within the implanted coronary scaffold have emerged. Dual antiplatelet therapy (DAPT) (compared to single antiplatelet therapy or anticoagulant) and initially prolonged DAPT (12 months) has offered a preventive treatment for stent thrombosis after PCI.\n\nPCI treatment for CTOs continues to increase in France and around the world, while no dedicated study has been proposed so far regarding DAPT duration. Therefore, the general European recommendations for DAPT in chronic coronary syndrome management guidelines should be applied even though the CTO poses specific technical challenges (long and multiple stenting length for example). Even if 6 months DAPT is recommended as routine duration in chronic coronary syndrome (CCS), longer DAPT (12 months) is possible in this setting. However, the optimal duration of DAPT is not clearly demonstrated on an individual basis and each physician must adapt the DAPT duration for each single patient. A so called \"ischemic \u002F bleeding balance \"guides the duration of DAPT.\n\nThis study would be the first randomized protocol to clarify the efficacy and safety of a shorter DAPT duration in the specific context of CTO PCI. It is conceivable that the technical advances which have made it possible to reduce the duration of DAPT to up to 1 month, in the cases of patients at high risk of bleeding for example, could be applicable to CTO PCI. Therefore, reducing the DAPT to 1 month, in the setting of CTO PCI, could reduce the haemorrhagic risk which should be proportional to the duration of the DAPT. Moreover, the invesitgators will evaluate the safety of short DAPT in terms of ischemic events during follow-up.",[24],"2023-12-15",{"date":81,"type":30},"2023-12-18",{"date":83,"type":20},"2024-03-30",{"date":85,"type":20},"2027-09-30",{"name":87,"class":37},"Assistance Publique Hopitaux De Marseille"]